Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Q1 2026 earnings

Reported May 14, 2026 · Before market open

EPS-$2.15Beat by $0.22
EPS estimate-$2.37

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$1.9M
EPS estimate-$2.50

Financials

Q1 2026

Income statement

See full
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$982.03M+385%
Enterprise value$1B+982%

Returns & leverage

See full
Current ratio6.5×+1.3×

FAQ

When did Inhibrx Biosciences, Inc. report Q1 2026 earnings?
Inhibrx Biosciences, Inc. (INBX) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Inhibrx Biosciences, Inc.'s Q1 2026 revenue and EPS?
Inhibrx Biosciences, Inc. reported eps of $-2.15 for Q1 2026.
Did Inhibrx Biosciences, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-2.37 by $0.22.
How did Inhibrx Biosciences, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 23.2% from $-2.80.
Where can I find Inhibrx Biosciences, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0002007919-26-000020) and the 10-Q periodic report (0002007919-26-000027) directly on SEC EDGAR. The filing index links above go to sec.gov.